Key result
Untreated obstructive CAD in TAVR recipients is not associated with higher mortality or MACE.
Why the study?
The optimal management of concomitant chronic obstructive CAD in TAVR recipients remains unknown, with some advocating for pre-TAVR PCI and others managing expectantly.
Does untreated chronic obstructive coronary artery disease worsen procedural and long-term outcomes in TAVR recipients?
Population
1911 TAVR recipients
Comparison
Stable non-obstructive CAD vs varying degrees of untreated obstructive CAD
Design
Retrospective cohort study
Follow-up
Median 21 months
Authors
Loading...
May support deferral of chronic obstructive CAD revascularization in TAVR; leaves open need for randomized confirmation.
Cohort (n=1,911)
Does untreated chronic obstructive coronary artery disease worsen procedural and long-term outcomes in TAVR recipients?
Absolute Event Rate: 94% vs 98%
p-value: p=< .001
TAVR can be performed safely in patients with untreated chronic obstructive CAD without increasing procedural complications or mortality, despite a slightly higher rate of unplanned revascularization and acute coronary syndrome at 1 year.
Persits et al. (2024) conducted a cohort in Chronic obstructive coronary artery disease in TAVR recipients (n=1,911). Untreated chronic obstructive CAD vs. Stable non-obstructive CAD was evaluated on Procedural all-cause mortality and complications, major adverse cardiovascular events, and post-TAVR unplanned coronary revascularization (p=< .001). Untreated chronic obstructive CAD in TAVR recipients did not increase mortality or MACE, with 1-year ACS and unplanned revascularization rates of 94% vs 98% for non-obstructive CAD (P<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: